Medline (NASDAQ:MDLN) Stock Has Consensus Price Target of $46.08

Medline (NASDAQ:MDLN) has been assigned an average recommendation of “Moderate Buy” from the twenty-nine research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and twenty-three have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $46.08.

A number of research analysts have recently weighed in on the stock. Tigress Financial reduced their target price on shares of Medline from $62.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings downgraded Medline from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, October 8th. Barclays reduced their price objective on Medline from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 9th. Robert W. Baird set a $42.00 target price on Medline in a research report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft set a $37.00 target price on Medline and gave the company a “hold” rating in a research note on Thursday, August 6th.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported Q3 EPS of $0.44, beating the $0.32 consensus estimate, with revenue of $7.86 billion. Shares gapped higher following the earnings report. Medline shares gap up following strong earnings
• Positive Sentiment: Analyst target increases add to the bullish outlook: UBS raised its target to $49 and maintained a Buy rating; Citi raised its target to $47 and kept Buy; and Leerink Partners lifted its target to $46 with an Outperform rating. UBS ratings Citi ratings Leerink Partners ratings
• Positive Sentiment: BTIG reaffirmed its Buy rating with a $55 target, while Barclays also assigned a Buy rating, adding to the favorable analyst sentiment. BTIG ratings Barclays rating
• Positive Sentiment: Medline plans price increases in 2027 to offset inflation, which could help protect revenue and profitability if customers accept the higher prices. Pricing plans and Q3 results

Insiders Place Their Bets

In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of Medline stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the sale, the insider owned 16,453,806 shares of the company’s stock, valued at approximately $576,705,900.30. This trade represents a 11.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 7,948,676 shares of company stock valued at $281,805,137. Company insiders own 0.81% of the company’s stock.

Hedge Funds Weigh In On Medline

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after purchasing an additional 254 shares during the period. Whipplewood Advisors LLC bought a new position in Medline in the 1st quarter worth approximately $30,000. Reyes Financial Architecture Inc. bought a new position in Medline in the 3rd quarter worth approximately $30,000. NewEdge Advisors LLC boosted its holdings in Medline by 100.0% in the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after buying an additional 475 shares during the period. Finally, Allworth Financial LP grew its stake in Medline by 86.2% in the 2nd quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock valued at $41,000 after buying an additional 487 shares in the last quarter.

Medline Price Performance

MDLN opened at $39.64 on Friday. Medline has a fifty-two week low of $31.37 and a fifty-two week high of $50.88. The firm has a 50-day moving average of $34.78 and a 200 day moving average of $39.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.61 and a current ratio of 4.04. The firm has a market cap of $52.12 billion and a P/E ratio of 90.09.

Medline (NASDAQ:MDLN) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.32 by $0.12. The business had revenue of $7.86 billion for the quarter. Medline had a net margin of 1.84% and a return on equity of 8.21%. On average, research analysts expect that Medline will post 1.50 EPS for the current year.

Medline Company Profile

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations.

The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations.

Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.